Journals / Türk Kardiyoloji Derneği Arşivi / 2007 / Cilt: 35 - Sayı: 7

Bazal kalp hızının beta-bloker tedavisinin antihipertansif etkinliği üzerine etkisi

The effect of basal heart rate on the antihypertensive efficiency of beta-blocker treatment

Pages
423–426
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: There were significant decreases in mean daytime systolic, diastolic, and arterial (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Beta-blockers are widely used in the treatment of hypertension.
📊
Key Findings & Data:Although decrease in heart rate has a major role in beta-blocker treatment, data are limited on the association between heart rate and the effectiveness of beta-blockers.
💡
Conclusion & Impact:Results: There were significant decreases in mean daytime systolic, diastolic, and arterial (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Beta-blockers are widely used in the treatment of hypertension. Although decrease in heart rate has a major role in beta-blocker treatment, data are limited on the association between heart rate and the effectiveness of beta-blockers. This study was designed to evaluate the effect of basal heart rate on the efficiency of beta-blocker treatment in patients with essential arterial hypertension.Study design: This prospective study included 20 patients (13 males, 7 females, mean age 53±10 years) with grade I/II essential hypertension, who did not receive any antihypertensive drugs and did not have any disease affecting the heart rate. Following 24-hour ambulatory blood pressure monitoring for daytime and nighttime systolic, diastolic, and arterial blood pressures, and mean heart rates, oral metoprolol succinate treatment (50 mg/day) was started. At the end of 20 days, 24-hour ambulatory blood pressure monitoring was repeated. Results: There were significant decreases in mean daytime systolic, diastolic, and arterial (p

Özet

Amaç: Beta-blokerler hipertansiyon tedavisinde yaygın olarak kullanılmaktadır. Beta-bloker tedavisinde kalp hızında azalmanın önemli bir rolü olmasına karşın, kalp hızı ile beta-blokerlerin etkinlikleri arasındaki ilişki hakkında çok az veri vardır. Bu çalışmada, esansiyel arteryel hipertansiyonlu hastalarda bazal kalp hızının beta-bloker tedavisinin antihipertansif etkinliği üzerindeki etkileri araştırıldı.Ça­lış­ma pla­nı: Bu ileriye dönük çalışmaya, antihipertansif tedavi görmeyen ve kalp hızını etkileyebilecek herhangi bir hastalığı olmayan, I/II derece esansiyel arteryel hipertansiyonlu 20 hasta (13 erkek, 7 kadın; ort. yaş 53±10) alındı. Tüm hastaların gündüz ve geceki sistolik, diyastolik ve arteryel kan basınçları ve kalp hızlarının belirlenmesi için 24 saatlik ambulatuvar kan basıncı izlemesine başvuruldu. Daha sonra, 50 mg/gün dozla oral metoprolol süksinat tedavisine başlandı. Yirmi gün sonunda 24 saatlik ambulatuvar kan basıncı izlemesi tekrarlandı. Bul­gu­lar: Tedavi sonunda güniçi ortalama sistolik, diyastolik ve arteryel kan basınçları anlamlı düşüş gösterdi (p

🔖

Cite This Article

CANBAY, A., DİKER, E., ÖZCAN, Ö., AYDOĞDU, S., BAYAR, N. (2022). Bazal kalp hızının beta-bloker tedavisinin antihipertansif etkinliği üzerine etkisi. Türk Kardiyoloji Derneği Arşivi, Cilt: 35 - Sayı: 7, 423–426. https://ajindex.com/articles/633643

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
  2. Moser M, Setaro J. Continued importance of diuretics and beta-adrenergic blockers in the management of hypertension. Med Clin North Am 2004;88:167-87
  3. Fung JW, Yu CM, Yip G, Chan S, Yandle TG, Richards AM, et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003;92:406-10
  4. Malacco E, Mailland F, Bosisio E, Meroni R, Dagani R, Renesto E, et al. Acute and long-term haemodynamic effects of propranolol and indenolol in hypertension. Eur J Clin Pharmacol 1986;30:157-60
  5. Prichard BN, Cruickshank JM, Graham BR. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press 2001;10:366-86
  6. Andersson B, Stromblad SO, Lomsky M, Waagstein F. Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol. Eur Heart J 1999;20:575-83
  7. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen Grandjean M, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001;103: 1428-33
  8. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61
  9. Copie X, Pousset F, Lechat P, Jaillon P, Guize L, Le Heuzey JY. Effects of beta-blockade with bisoprolol on heart rate variability in advanced heart failure: analysis of scatterplots of R-R intervals at selected heart rates. Am Heart J 1996;132(2 Pt 1):369-75
  10. Belz GG, Breithaupt K, Erb K, Kleinbloesem CH, Wolf GK. Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta-blocker propranolol and their combination on haemodynamics in hypertension. J Hypertens 1989;7:817-24
  11. Messerli FH, Grossman E. Beta-blockers in hypertension: is carvedilol different? Am J Cardiol 2004; 93(9A):7B-12B
  12. Fleg JL, Schulman S, O’Connor F, Becker LC, Gerstenblith G, Clulow JF, et al. Effects of acute beta-adrenergic receptor blockade on age-associated changes in cardiovascular performance dur